Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.

NCT02063113•Nantes University Hospital

Summary

The aim of this study is to determine whether the presence of vulnerability detected by geriatricians is associated with treatment discontinuation in older patient. During the comprehensive geriatric assessment realized before the decision-treatment, the following data are recorded and their impact in the therapeutic changes will also be analysed: comorbidity, age, depression, functional status, the cognitive impairment and malnutrition.

Eligibility

Age

70 - 100 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients aged 70 years and older
•Patients referred for a assessment of a newly diagnosed multiple myeloma
•Patients for who the initial therapy proposed is either melphalan-prednisone-thalidomide or melphalan-prednisone-bortezomib or included in a phase 3 trial.
•Patients who provide informed written consent

Exclusion Criteria

•Patients who refuse the study
•Patients who won't have therapy
•Patients can't respond to geriatric assessment because of severe cognitive disorder
•Patients with a legal guardian

Locations (2)

CHD Vendée La Roche sur Yon

La Roche-sur-Yon, France

CHU de Nantes

Nantes, France

Key Dates

Start Date

May 19, 2014

Primary Completion Date

November 28, 2018

Completion Date

November 28, 2018

Last Updated

May 23, 2023

Enrollment

ACTUAL participants

Conditions

Multiple Myeloma in Older Patients

Interventions

Vulnerability and therapeutic changes in older patients with multiple myeloma.

OTHER